Benefits and Risks of Long-Term Asthma Management in Children: Where Are We Heading?

Hengameh H. Raissy () and H. William Kelly
Additional contact information
Hengameh H. Raissy: University of New Mexico, School of Medicine
H. William Kelly: University of New Mexico, School of Medicine

Drug Safety, 2017, vol. 40, issue 3, No 2, 210 pages

Abstract: Abstract International guidelines provide recommendations for a stepwise approach to the management of asthma in children 0–4 years old, 5–11 years old, and adolescents who are treated as adults. Therapy is aimed at two domains of control: current impairment and future risk. The long-term controller medications, inhaled corticosteroids (ICSs), ICSs in combination with long-acting β2 agonists, leukotriene receptor antagonists, and immunomodulators, exhibit different efficacies for these domains. The risk:benefit ratios of the available medications need to be carefully assessed. This review briefly presents the benefits and the potential risks of available asthma medications in children to assist the practitioner in the optimal use of asthma medications. Specifically, the systemic activity of the ICSs and how to minimize their effects on growth and adrenal activity are reviewed as well as other potential adverse effects. Dosing strategies such as intermittent therapy are also assessed.

Keywords: Budesonide; Fluticasone Propionate; Montelukast; Omalizumab; Zafirlukast (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-016-0483-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:40:y:2017:i:3:d:10.1007_s40264-016-0483-0

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-016-0483-0

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().